A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : CDA / cytidine deaminase

[Related PubMed/MEDLINE]
Total Number of Papers: 195
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   CDA  (>> Co-occurring Abbreviation)
Long Form:   cytidine deaminase
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2022 5'-nucleotidase, cytosolic II genotype, and clinical outcome in patients with acute myeloid leukemia with intermediate-risk cytogenetics. AML, DFS, NT5C2, OS
2022 Cytidine deaminase activity increases in the blood of breast cancer patients. BC, RT
2022 Cytidine deaminase deficiency in tumor cells is associated with sensitivity to a naphthol derivative and a decrease in oncometabolite levels. ---
2022 Differences in actionable genomic alterations between brain metastases and non‑brain metastases in patients with non‑small cell lung cancer. ALK, BM, CoA, ctDNA, DNA, NGS, NSCLC, SMAD4, SOD2, VHL
2022 DNA methylome and single-cell transcriptome analyses reveal CDA as a potential druggable target for ALK inhibitor-resistant lung cancer therapy. ALK, EMT, NSCLC, sc
2022 Hypermutation of specific genomic loci of Pseudomonas putida for continuous evolution of target genes. 5-FOA, UDG
2022 Modification of tomato breeding traits and plant hormone signaling by target-AID, the genome-editing system inducing efficient nucleotide substitution. GA, SlETR1, Target-AID
2022 Penetrating Micelle for Reversing Immunosuppression and Drug Resistance in Pancreatic Cancer Treatment. alpha-SMA, GEM, M2-TAMs, PDAC, STAT3, T-regs, TME
2021 A pilot clinical trial of oral tetrahydrouridine/decitabine for noncytotoxic epigenetic therapy of chemoresistant lymphoid malignancies. DNMT1
10  2021 Cedazuridine/decitabine: from preclinical to clinical development in myeloid malignancies. C-DEC, CMML, FDA, HMAs, MDS
11  2021 Chemotherapy-induced CDA expression renders resistant non-small cell lung cancer cells sensitive to 5'-deoxy-5-fluorocytidine (5'-DFCR). 5'-DFCR, NSCLC, TYMP
12  2021 Cytidine deaminase can deaminate fused pyrimidine ribonucleosides. ---
13  2021 hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. 5-FU
14  2021 HYAL4-V1/Chondroitinase (Chase) Drives Gemcitabine Resistance and Predicts Chemotherapy Failure in Patients with Bladder Cancer. MIBC, WT
15  2021 In vitro assessment of a synergistic combination of gemcitabine and zebularine in pancreatic cancer cells. GEM, PDAC, Zeb
16  2021 m6A Methyltransferase METTL14-Mediated Upregulation of Cytidine Deaminase Promoting Gemcitabine Resistance in Pancreatic Cancer. ChIP, dCK, m6A
17  2021 Pharmacokinetics and pharmacogenetics of liposomal cytarabine in AML patients treated with CPX-351. AML, EM, PK, PM
18  2021 RRM1 Expression as a Prognostic Biomarker for Unresectable or Recurrent Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin. BTC, dCK, GP, hENT1, OS, PFS
19  2021 Silylation of Deoxynucleotide Analog Yields an Orally Available Drug with Antileukemia Effects. AML, DAC, MDS
20  2021 Zebularine suppressed gemcitabine-induced senescence and improved the cellular and plasma pharmacokinetics of gemcitabine, augmented by liposomal co-delivery. HRP, PSL
21  2021 [Establishment of Cytarabine-resistant Acute Lymphoblastic Leukemia Cell Lines and Its Resistance Mechanism]. ALL, dCK
22  2020 A decrease in NAMPT activity impairs basal PARP-1 activity in cytidine deaminase deficient-cells, independently of NAD. NAMPT, PARP-1, UFB
23  2020 A pilot clinical trial of the cytidine deaminase inhibitor tetrahydrouridine combined with decitabine to target DNMT1 in advanced, chemorefractory pancreatic cancer. DNMT1, PD, PDAC, THU
24  2020 Characterizing metabolites and potential metabolic pathways changes to understanding the mechanism of medicinal plant Phellodendri Amurensis cortex against doxorubicin-induced nephritis rats using UPLC-Q/TOF-MS metabolomics. Ass, MTAP, PAC, TK
25  2020 Correlation Between the Metabolic Conversion of a Capecitabine Metabolite, 5'-Deoxy-5-fluorocytidine, and Creatinine Clearance. 5'-DFCR, 5'-DFUR, 5-FU, AUC, CLCR
26  2020 Crystal structure of Arabidopsis thaliana cytidine deaminase. ---
27  2020 Development of gemcitabine-resistant patient-derived xenograft models of pancreatic ductal adenocarcinoma. dCK, GemR, hCNT1, hENT1, PDAC, PDX, RRM1
28  2020 Downregulation of GLI3 Expression Mediates Chemotherapy Resistance in Acute Myeloid Leukemia. ABCC11, AML, GLI, Hh, MRP8, SAMHD1, shRNA
29  2020 Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancer. BTC, dCK, PDX
30  2020 Mechanistic Multiscale Pharmacokinetic Model for the Anticancer Drug 2',2'-difluorodeoxycytidine (Gemcitabine) in Pancreatic Cancer. AUC, dFdCTP
31  2020 MUC1 oncoprotein mitigates ER stress via CDA-mediated reprogramming of pyrimidine metabolism. MUC1, ROS, UPR
32  2020 Oral Azacitidine and Cedazuridine Approximate Parenteral Azacitidine Efficacy in Murine Model. AML, AZA, CDX, CDZ, DEC, DNMTis, i.v, MDS, PDX, s.c, VEN
33  2020 Pharmacokinetics of gemcitabine and its amino acid ester prodrug following intravenous and oral administrations in mice. PEPT1, V-Gem
34  2020 Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma. CON, HR, ORR, OS, PDAC, PFS, QoL, SEQ
35  2019 An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study. AUC
36  2019 Associations of cytosine deaminase gene polymorphisms with effectiveness of gemcitabine/cisplatin chemotherapy in patients of Xinjiang Uyghur and Han nationality with non-small cell lung cancer. HR, NSCLC, OR
37  2019 Biochemical and structural analysis of the Klebsiella pneumoniae cytidine deaminase CDA. ---
38  2019 Contribution of Cytidine Deaminase to Thymidylate Biosynthesis in Trypanosoma brucei: Intracellular Localization and Properties of the Enzyme. CDAs, dUTPase, RNAi, TbCDA
39  2019 Determinants of the interindividual variability in serum cytidine deaminase activity of patients with solid tumours. SNPs
40  2019 Differential Inhibition of APOBEC3 DNA-Mutator Isozymes by Fluoro- and Non-Fluoro-Substituted 2'-Deoxyzebularine Embedded in Single-Stranded DNA. 5FdZ, dZ-containing, ss
41  2019 Intracellular Cytidine Deaminase Regulates Gemcitabine Metabolism in Pancreatic Cancer Cell Lines. PDAC
42  2019 Multiplex Gene Disruption by Targeted Base Editing of Yarrowia lipolytica Genome Using Cytidine Deaminase Combined with the CRISPR/Cas9 System. DSB, NHEJ
43  2019 Regulation of drug metabolizing enzymes in the leukaemic bone marrow microenvironment. AML, BM, MM
44  2019 Simultaneous determination of cytosine arabinoside and its metabolite uracil arabinoside in human plasma by LC-MS/MS: Application to pharmacokinetics-pharmacogenetics pilot study in AML patients. AML, AraC
45  2019 Systematic exploration of Astragalus membranaceus and Panax ginseng as immune regulators: Insights from the comparative biological and computational analysis. ADME, AM, ChAT, PG, SphK1, TCM, WES
46  2019 The augmented expression of the cytidine deaminase gene by 5-azacytidine predicts therapeutic efficacy in myelodysplastic syndromes. 5-AC, MDS
47  2019 The Emerging Role of Cytidine Deaminase in Human Diseases: A New Opportunity for Therapy? ---
48  2019 The MitoNEET Ligand NL-1 Mediates Antileukemic Activity in Drug-Resistant B-Cell Acute Lymphoblastic Leukemia. ALL
49  2018 CDA as a predictive marker for life-threatening toxicities in patients with AML treated with cytarabine. AML, PM
50  2018 CDA gene silencing regulated the proliferation and apoptosis of chronic myeloid leukemia K562 cells. CML, RT-qPCR
51  2018 Cytidine deaminase enzymatic activity is a prognostic biomarker in gemcitabine/platinum-treated advanced non-small-cell lung cancer: a prospective validation study. ---
52  2018 Dihydroartemisinin increases gemcitabine therapeutic efficacy in ovarian cancer by inducing reactive oxygen species. DHA, GEM, ROS
53  2018 Gene expression of hENT1, dCK, CDA, dCMPD and topoisomerase IIα as an indicator of chemotherapy response in AML treated with cytarabine and daunorubicin. dCMPD, DFS, Topo-IIa
54  2017 Cytidine deaminase deficiency impairs sister chromatid disjunction by decreasing PARP-1 activity. BS, UFB
55  2017 DCK expression, a potential predictive biomarker in the adjuvant gemcitabine chemotherapy for biliary tract cancer after surgical resection: results from a phase II study. BTC, dCK, hENT1, RFS
56  2017 Development of a Gemcitabine-Polymer Conjugate with Prolonged Cytotoxicity against a Pancreatic Cancer Cell Line. GEM, NPs, RAFT
57  2017 DNA mutagenic activity and capacity for HIV-1 restriction of the cytidine deaminase APOBEC3G depend on whether DNA or RNA binds to tyrosine 315. A3G, ss
58  2017 Next-generation sequencing reveals lymph node metastasis associated genetic markers in colorectal cancer. BCL10, BCL2, BRCA1, CNVs, EGF, EPHX1, ETV1, LSM3, MAP3K1, MST1R, NFKB1, PMS2, RALY, RRM2, SLC28A3, SNPs, TTF-1
59  2017 Novel Genetic Variants in Carboxylesterase 1 Predict Severe Early-Onset Capecitabine-Related Toxicity. CES1, Cp, HFS
60  2017 Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study. AEs, CRP, DNMT1, F-cells, RBCs, SCD, THU
61  2017 Population Pharmacokinetics of Gemcitabine and dFdU in Pancreatic Cancer Patients Using an Optimal Design, Sparse Sampling Approach. PK
62  2016 A balanced pyrimidine pool is required for optimal Chk1 activation to prevent ultrafine anaphase bridge formation. UFB
63  2016 Combined treatment, based on lysomustine administration with mesenchymal stem cells expressing cytosine deaminase therapy, leads to pronounced murine Lewis lung carcinoma growth inhibition. 5-FC, AT-MSCs, CDA/UPRT, LLC
64  2016 Cytidine Deaminase Deficiency Reveals New Therapeutic Opportunities against Cancer. ---
65  2016 Efficacy and epigenetic interactions of novel DNA hypomethylating agent guadecitabine (SGI-110) in preclinical models of hepatocellular carcinoma. HCC
66  2016 High expression of the human equilibrative nucleoside transporter 1 gene predicts a good response to decitabine in patients with myelodysplastic syndrome. dCK, hENT1, LINE-1, MDS
67  2016 Lurbinectedin induces depletion of tumor-associated macrophages, an essential component of its in vivo synergism with gemcitabine, in pancreatic adenocarcinoma mouse models. CI, PDA, TAMs
68  2016 Of the Nine Cytidine Deaminase-Like Genes in Arabidopsis, Eight Are Pseudogenes and Only One Is Required to Maintain Pyrimidine Homeostasis in Vivo. NSH1
69  2016 Pyrimidine Salvage Enzymes Are Essential for De Novo Biosynthesis of Deoxypyrimidine Nucleotides in Trypanosoma brucei. TK
70  2015 Acquired resistance to decitabine and cross-resistance to gemcitabine during the long-term treatment of human HCT116 colorectal cancer cells with decitabine. CRC, DAC, dCK, DNMT1, GEM, SFRP1
71  2015 An enzymatic assay for high-throughput screening of cytidine-producing microbial strains. HPLC
72  2015 CDA directs metabolism of epigenetic nucleosides revealing a therapeutic window in cancer. 5cadC, 5fdC, 5hmdC, 5mdC
73  2015 Cytidine Deaminase as a Molecular Predictor of Gemcitabine Response in Patients with Biliary Tract Cancer. BTC, dCK, hCNT3, hENT1, RRM1, SNPs
74  2015 Cytidine Deaminase Axis Modulated by miR-484 Differentially Regulates Cell Proliferation and Chemoresistance in Breast Cancer. ---
75  2015 Cytidine deaminase polymorphism predicts toxicity of gemcitabine-based chemotherapy. HR, OR, ORR, OS
76  2015 Cytidine deaminase polymorphisms and worse treatment response in normal karyotype AML. AK-AML, AML, ara-U, NC, NK-AML
77  2015 FFCD-1004 Clinical Trial: Impact of Cytidine Deaminase Activity on Clinical Outcome in Gemcitabine-Monotherapy Treated Patients. ---
78  2015 Lethal toxicity after administration of azacytidine: implication of the cytidine deaminase-deficiency syndrome. PM
79  2015 Mycoplasma hyorhinis-encoded cytidine deaminase efficiently inactivates cytosine-based anticancer drugs. ---
80  2015 Pyrimidine Pool Disequilibrium Induced by a Cytidine Deaminase Deficiency Inhibits PARP-1 Activity, Leading to the Under Replication of DNA. BS
81  2015 RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia. AML, dCK, DNR, ENT1, RI, RRM1
82  2015 The influence of cytidine deaminase -33delC polymorphism on treatment outcome with high-dose cytarabine in Chinese patients with relapsed acute myeloid leukaemia. AML, CI, OR, SNPs
83  2015 Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice. GEM, LB, MSNP, PTX
84  2014 Association of xeroderma pigmentosum group D (Asp312Asn, Lys751Gln) and cytidine deaminase (Lys27Gln, Ala70Thr) polymorphisms with outcome in Chinese non-small cell lung cancer patients treated with cisplatin-gemcitabine. NSCLC, OS, TTP, XPD
85  2014 Clinical potential of elacytarabine in patients with acute myeloid leukemia. AML, hENT1
86  2014 Design, synthesis, and pharmacological evaluation of fluorinated tetrahydrouridine derivatives as inhibitors of cytidine deaminase. THU
87  2014 Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors. GO, GR, HDAC
88  2014 Recipient/donor contradictory genotypes with impact on drug pharmacogenetics after liver transplant: a deadly gift? ---
89  2014 Role of cytidine deaminase in toxicity and efficacy of nucleosidic analogs. ---
90  2014 Selection of the best blood compartment to measure cytidine deaminase activity to stratify for optimal gemcitabine or cytarabine treatment. ---
91  2014 SGI-110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome. DNMT
92  2014 The impact of CDA A79C gene polymorphisms on the response and hematologic toxicity in gemcitabine-treated patients: a meta-analysis. CI, NSCLC, RR
93  2013 Determination of common genetic variants in cytidine deaminase (CDA) gene in Indian ethnic population. PCR
94  2013 Higher capecitabine AUC in elderly patients with advanced colorectal cancer (SWOGS0030). 5-FU, AUC, DFUR
95  2013 Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy. AML, DNMT1, HPLC, MDS, OS
96  2013 Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase. PDA, TAMs
97  2012 Association of polymorphisms of cytosine arabinoside-metabolizing enzyme gene with therapeutic efficacy for acute myeloid leukemia. AML, dCK, MALDI-TOF MS, SNPs, WBC
98  2012 Cytidine deaminase genetic variants influence RNA expression and cytarabine cytotoxicity in acute myeloid leukemia. AML
99  2012 Flight of a cytidine deaminase complex with an imperfect transition state analogue inhibitor: mass spectrometric evidence for the presence of a trapped water molecule. FT-ICR MS
100  2012 Genetic polymorphisms of drug metabolizing enzymes and transporters: the long way from bench to bedside. GWAS, PXR